12/21/2023 0 Comments Ecto proctologist![]() Stella J, Bavaresco L, Braganhol E, Rockenbach L, Farias PF, Wink MR, Azambuja AA, Barrios CH, Morrone FB, Oliveira Battastini AM (2010) Differential ectonucleotidase expression in human bladder cancer cell lines. Shabbir M, Burnstock G (2009) Purinergic receptor-mediated effects of adenosine-5′-triphosphate in urological malignant deseases. Urology 68:549–553īurnstock G (2002) Potential therapeutic targets in the rapidly expanding field of purinergic signalling. Cancer Immunol Immunother 54:414–423Īvritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS (2006) Clinical model of lifetime cost of treating bladder cancer and associated complications. Schenk-Braat EA, Bangma CH (2005) Immunotherapy for superficial bladder cancer. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, Jia W, Chen J, Yang S, Zhou F, Zhao X, Wan S, Ye R, Liang C, Liu Z, Huang P, Liu C, Jiang H, Wang Y, Zheng H, Sun L, Liu X, Jiang Z, Feng D, Chen J, Wu S, Zou J, Zhang Z, Yang R, Zhao J, Xu C, Yin W, Guan Z, Ye J, Zhang H, Li J, Kristiansen K, Nickerson ML, Theodorescu D, Li Y, Zhang X, Li S, Wang J, Yang H, Wang J, Cai Z (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Rev Cancer 5:713–725Īriel I, Ayesh S, Gofrit O, Ayesh B, Abdul-ghani R, Pizov G, Smith Y, Sidi AA, Birman T, Schneider T, de Groot N, Hochberg A (2004) Gene expression in the bladder carcinoma rat model. ![]() ![]() Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Rivas A, Burzio V, Landerer E, Borgna V, Gatica S, Ávila R, López C, Villota C, de la Fuente R, Echenique J, Burzio LO, Villegas J (2012) Determination of the differential expression of mitochondrial long non-coding RNAs as noninvasive diagnosis of bladder cancer. Van Roekel EH, Cheng KK, James ND, Wallace DM, Billingham LJ, Murray PG, Bryan RT, Zeegers MP (2013) Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumours at diagnosis. Accessed 10 January 2013.īachir BG, Kassouf W (2012) Cause–effect? Understanding the risk factors associated with bladder cancer. World Health Organization Classification of Tumours. (2004) Pathology and genetics of tumours of the urinary system and male genital organs. BJU Int 101:106–112Įble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Shabbir M, Ryten M, Thompson C, Mikhailidis D, Burnstock G (2007) Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. The altered expression of NTPDase3 and ecto-5′-nucleotidase/CD73 presented herein adds further evidence to support the idea that alterations in ectonucleotidases are involved in bladder tumorigenesis and reinforce the ecto-5′-nucleotidase/CD73 as a future biomarker and/or a target for pharmacological therapy of bladder cancer.īurnstock G (2001) Therapeutic potential of purinergic signaling for diseases of the urinary tract. The cancerous urothelium, from mice that received BBN for 18 and 24 weeks, presented a weak immunostaining to NTPDase3, in contrast to an increased expression of ecto-5′-nucleotidase/CD73. After 18 weeks, mice’s bladder has developed histological alterations similar to human transitional cell carcinoma. The bladder of animals which has received BBN had alterations, mainly inflammation, in initial times of tumor induction. After this period, mice bladders were removed for histopathology analysis and immunofluorescence assays. Bladder tumor was induced in mice by the addition of 0.05 % of N-butyl-N-(hydroxybutyl)-nitrosamine (BBN) in the drinking water for 4, 8, 12, 18, and 24 weeks. In this work, we investigated the NTPDase3 and ecto-5′-nucleotidase/CD73 expression in cancer progression in vivo. The ectonucleotidases, mainly ecto-5′-nucleotidase/CD73 have been revealed as new players in cancer progression and malignity. One of the recent findings was the identification that the purinergic system was involved in bladder tumorigenesis. Then, researches continue looking for better therapeutic targets which can end up in new and more efficient treatments. The current treatments for this malignancy are not efficient to prevent the recurrence and progression of tumors. According to the World Health Organization, bladder cancer is the seventh most common cancer among men in the world.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |